Le Lzard
Classified in: Health, Science and technology, Covid-19 virus
Subject: Product/Service

Akston Biosciences Announces Publication in Vaccine of Positive Data for a Room Temperature Protein Subunit COVID-19 Vaccine

Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced publication of positive results from a 60-subject, open-label, Phase I trial of AKS-452, its shelf stable protein subunit COVID-19 vaccine candidate. The adjuvanted vaccine was generally well-tolerated and produced a 100% seroconversion rate in the 90 g single-dose regimen, as well as in the 45 g and 90 g two-dose regimens. The article in the current issue of Vaccine is available here.

The trial met all primary and secondary endpoints, indicating minimal reactogenicity and optimized immunogenicity. These results were subsequently confirmed in a Phase II trial.

A recombinant subunit vaccine, AKS-452 comprises an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor binding domain (RBD) antigen that is engineered to preserve effectiveness against viral variants.

"An effective COVID vaccine that is transportable without cold chain and is substantially less expensive than current vaccines ? with cost savings also attributable to Akston's high volume, low-cost manufacturing platform ? can address many of the shortcomings that have slowed distribution and vaccine access in countries around the world," said Todd Zion, Ph.D., President & CEO of Akston Biosciences. "A single production line can rapidly produce more than a billion doses of AKS-452 per year using established antibody production infrastructure available worldwide, creating an abundant vaccine resource."

The single-center, open-label Phase I dose-finding and safety study was conducted in the Netherlands with 60 healthy adults (18?65 years) receiving one or two doses 28 days apart of 22.5 g, 45 g, or 90 g of AKS-452. A 100% seroconversion rate was achieved in the 90 g cohort at 28 days, and in the 90- and 45 g cohorts at 56 days. AEs were mild and comparable to those with currently approved vaccines. There were no SAEs.

A Phase II/III trial for primary vaccination is expected to begin in India in Q1 2022, and studies evaluating AKS-452 as a booster are being planned.

About AKS-452

Based on Akston's proprietary Fc fusion protein platform, AKS-452 is a SARS CoV-2 protein subunit vaccine designed to induce a Th1/Th2 mixed immune response in patients against the Receptor Binding Domain (RBD) of the novel coronavirus spike protein. As the primary locus for infection, the RBD is highly conserved among mutated forms of the virus, and preclinical studies have demonstrated robust antibody neutralization of the B.1.1.7 (Alpha) and B.1.351 (Gamma) variants. The vaccine has been engineered to use standard, low-cost, antibody manufacturing techniques, such that a single production line could be capable of producing over one billion doses per year.

About Akston Biosciences

Akston Biosciences Corporation leverages its novel fusion protein platform to develop and manufacture new classes of biologics, including vaccines, ultra-long-acting insulins, and autoimmune disease therapies. Founded by the team that developed the world's first clinical glucose-responsive insulin at SmartCells, Inc. (sold to Merck & Co.), Akston has partnered with Dechra Pharmaceuticals PLC (DPH) to commercialize once-a-week canine and feline insulin therapies. It operates a GMP biologics manufacturing facility and research laboratory at its Beverly, Mass. location. www.akstonbio.com.

These press releases may also interest you

at 00:59
This year, Cityremovalist customers mentioned soaring rent prices as the number one reason for needing to relocate to more affordable accommodation, followed by looking for a suburb where the cost of living is reasonably priced, COVID and job loss...

at 00:00
High Arctic Energy Services Inc. (the "Corporation" or "High Arctic") released its' second quarter results today. Mike Maguire, Chief Executive Officer commented: "The sale of our Canadian well servicing business provided a compelling...

11 ao 2022
NorthWest Healthcare Properties Real Estate Investment Trust (the "REIT") , today announced its results for the three and six months ended June 30, 2022. NorthWest's inflation indexed $10.2 billion, 232 property portfolio performed well in the second...

11 ao 2022
NXT Energy Solutions Inc. ("NXT" or the "Company") today announced the Company's financial and operating results for the quarter ended June 30, 2022. All dollar amounts herein are in Canadian Dollars unless otherwise identified. Q2 Financial and...

11 ao 2022
Allied Market Research recently published a report, titled, "Satellite Connectivity Market by Component (Video, Fixed, Mobility), by Orbit (Elliptical, GEO, LEO, MEO), by End User (Civil and Earth Observation, Government and Military, Commercial):...

11 ao 2022
Received zoning approvals for over 3.8 million square feet of residential development in the second quarter on 3 projects in the Greater Toronto Area, including Vaughan, Scarborough, and Pickering;In excess of 3.0 million square feet of construction...

News published on 8 february 2022 at 09:25 and distributed by: